Emergent BioSolutions Secures 3-Year Canadian Standing Offer for NARCAN Nasal Spray
Event summary
- Emergent BioSolutions awarded a standing offer by the Government of Canada to supply NARCAN® Nasal Spray from October 1, 2026, through September 30, 2029, with an option to extend for two additional years.
- The standing offer allows federal, provincial, and territorial organizations in Canada to procure NARCAN® Nasal Spray through individual call-ups.
- NARCAN® Nasal Spray is the only 4 mg, intranasal naloxone spray in Canada with a shelf life of four years.
- This award follows an existing 5-year standing offer between Emergent and the Government of Canada set to expire in September 2026.
The big picture
This standing offer underscores the critical role of naloxone in combating the opioid crisis in Canada. Emergent BioSolutions' ability to secure long-term government contracts highlights its strategic positioning in the public health sector. The contract's extension option suggests potential for sustained revenue and market dominance in opioid overdose emergency treatments.
What we're watching
- Market Expansion
- How Emergent BioSolutions will leverage this standing offer to expand its market presence in Canada and potentially other regions.
- Regulatory Compliance
- Whether Emergent can maintain compliance with Canadian regulatory standards and procurement processes over the contract duration.
- Revenue Stability
- The pace at which Emergent can secure additional government contracts to stabilize its revenue stream from NARCAN® Nasal Spray.